Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

The aim of our study was to investigate the influence of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients....

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2019-02, Vol.21 (1), p.66-66, Article 66
Main Authors: Hernández-Breijo, Borja, Plasencia-Rodríguez, Chamaida, Navarro-Compán, Victoria, Martínez-Feito, Ana, Jochems, Andrea, Kneepkens, Eva L, Wolbink, Gerrit J, Rispens, Theo, Diego, Cristina, Pascual-Salcedo, Dora, Balsa, Alejandro
Format: Article
Language:English
Subjects:
Adalimumab
Adalimumab - therapeutic use
Adult
Antirheumatic agents
Antirheumatic Agents - chemical synthesis
Antirheumatic Agents - therapeutic use
Arthritis
Axial spondyloarthritis
Body Mass Index
Clinical response
Concomitant csDMARDs
Drug therapy
Drug Therapy, Combination
Enzyme-linked immunosorbent assay
Female
Humans
Infliximab
Infliximab - therapeutic use
Logistic Models
Male
Medical research
Middle Aged
Monoclonal antibodies
Necrosis
Obesity
Overweight
Overweight - complications
Overweight - drug therapy
Overweight persons
Prospective Studies
Remission Induction
Spondylarthritis - complications
Spondylarthritis - drug therapy
Spondyloarthropathies
Testing
TNF inhibitors
Tumor necrosis factor
Tumor necrosis factor inhibitors
Tumor Necrosis Factor Inhibitors - therapeutic use
Tumor necrosis factor-TNF
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of our study was to investigate the influence of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients. Prospective observational study during 1 year with 2 cohorts (Madrid and Amsterdam) including 180 axSpA patients treated with standard doses of infliximab or adalimumab. Patients were stratified by BMI, being 78 (43%) normal weight (18.5-24.9 kg/m ) and 102 (57%) overweight/obese (≥ 25.0 kg/m ). After the first year of treatment, TNFi trough levels were measured by capture ELISA. Clinical response to TNFi was defined as ∆BASDAI ≥ 2 and clinical remission as BASDAI 
ISSN:1478-6362
1478-6354
1478-6362
DOI:10.1186/s13075-019-1849-3